Johnson and Johnson to acquire Joint Medical Products:
This article was originally published in Clinica
Johnson & Johnson has signed a definitive agreement to purchase hip and knee prosthesis company Joint Medical Products. Subject to clearance under the Hart-Scott-Rodino Act, the transaction is expected to close within 120 days.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.